CD14 + HLADR - blood values in patients after alloHSCT are highly predictive of survival and infectious complications

Transpl Immunol. 2021 Apr:65:101370. doi: 10.1016/j.trim.2021.101370. Epub 2021 Jan 20.

Abstract

Background: Cytokine storm described in patients after allogeneic haematopoietic stem cell transplantation (alloHSCT) is associated with the appearance of CD14 + HLADR - in the blood.

Methods: To study the role of CD14 + HLADR - cells 223 patients after alloHSCT followed from 1 month to 15 years. The methods used included flow cytometry for blood cells profiling, nucleic acid tests for viral reactivation, and physician care according to the Polish and international guidelines.

Results: We found that CD14 + HLADR - peak values determined during the first 60 post-transplant days were higher in the patients who died than in those who survived in this time interval (mean ± SEM: 3.78 ± 0.67% vs 2.38 ± 0.65%, p < 0.001). Receiver operating characteristic (ROC) analysis showed that CD14 + HLADR - cells level in the blood at cut-off point at 0.71% discriminated the patients as to survival; the patients above the threshold had poorer survival (Kaplan-Meier curve covering 15-year observation) than those below (0.19 vs 0.46, p < 0.001). Infections prevailed other causes of death in the high blood CD14 + HLADR - group (0.61 vs 0.38, p = 0.057). ROC analysis defined the CD4+ blood level at 17.70% as not significantly associated with survival. Multivariate analysis revealed that CD14 + HLADR - cells (HR = 3.47, p < 0.001) and the presence of acute graft-versus-host disease (aGvHD) grade ≥ 3 (HR = 3.82, p = 0.005) adversely impacted the survival.

Conclusions: CD14 + HLADR - cells can serve as a biomarker for the risk of fatal complications frequently associated with infections.

Keywords: Allogeneic haematopoietic stem cell transplantation; CD14 + HLADR -; Monocytic-marrow derived suppressor cells; Post transplant fatal complications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Graft vs Host Disease* / diagnosis
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Retrospective Studies